高级检索
当前位置: 首页 > 详情页

MTA2 promotes the metastasis of esophageal squamous cell carcinoma via EIF4E-Twist feedback loop.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [2]Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [3]Department of Fifth Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [4]Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
出处:
ISSN:

关键词: EIF4E ESCC metastasis MTA2 Twist

摘要:
Metastasis-associated protein 2 (MTA2) is frequently amplified in many types of cancers; however, the role and underlying molecular mechanism of MTA2 in esophageal squamous cell carcinoma (ESCC) remain unknown. Here, we reported that MTA2 is highly expressed in ESCC tissue and cells, and is closely related to the malignant characteristics and poor prognosis of patients with ESCC. Through in vitro and in vivo experiments, we demonstrated that MTA2 significantly promoted ESCC growth, metastasis, and epithelial-mesenchymal transition (EMT) progression. This integrative analysis combined with expression microarray showed that MTA2 could interact with eukaryotic initiation factor 4E (EIF4E), which positively regulates the expression of Twist, known as a master regulator of EMT. Moreover, the results of chromatin immunoprecipitation revealed that MTA2 was recruited to the E-cadherin promoter by Twist, which reduced the acetylation level of the promoter region and thus inhibited expression of E-cadherin, and subsequently promoted the aggressive progression of ESCC. Collectively, our study provided novel evidence that MTA2 plays an aggressive role in ESCC metastasis by a novel EIF4E-Twist positive feedback loop, which may provide a potential therapeutic target for the management of ESCC. © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2021]版:
Q2 ONCOLOGY
最新[2023]版:
Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
共同第一作者:
通讯作者:
通讯机构: [1]Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [*1]Research Center, The Fourth Hospital of Hebei Medical University, 12 Jiankang road, Shijiazhuang, Hebei 050011, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号